Die somatische Behandlung der unipolaren depressiven Störungen. Teil 1

Holsboer‐Trachsler, Edith; Hättenschwiler, J; Beck, John C.; Brand, Sarah; Hemmeter, U.; Keck, ME; Rennhard, S; Hatzinger, Martin; Merlo, M.C.G.; Bondolfi, Guido; Preisig, Martin; Andreoli, Y Attinger; Gehret, A; Bielinski, D; Seifritz, Erich

doi:10.4414/smf.2010.07340

Cited by 6 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This enzyme also affects a large number of drugs [25] including SSRIs [26,29], opioids [29], and in particular the bioactivation of clopidogrel [31]. However, none of the Swiss DL contained the biomarker ABCB1, although the Swiss guideline on the treatment of unipolar depressive episodes recommends to test for selected genetic variants of ABCB1 (P-Glycoprotein) in patients taking antidepressants [32][33][34].…”

Section: Discussionmentioning

confidence: 99%

Pharmacogenetic information in Swiss drug labels – a systematic analysis

et al. 2020

View full text Add to dashboard Cite

Implementation of pharmacogenetics (PGx) and individualization of drug therapy is supposed to obviate adverse drug reactions or therapy failure. Health care professionals (HCPs) use drug labels (DLs) as reliable information about drugs. We analyzed the Swiss DLs to give an overview on the currently available PGx instructions. We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB. From 5979 hits, 2564 were classified as PGx-relevant affecting 167 substances. 55% (n = 93) were classified as “actionable PGx”. Frequently, PGx information appeared in the pharmacokinetics section and in DLs of the anatomic group “nervous system”. Unstandardized wording, appearance of PGx information in different sections and unclear instructions challenge HCPs to identify and interpret PGx information and translate it into practice. HCPs need harmonization and standardization of PGx information in DLs to personalize drug therapies and tailor pharmaceutical care.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacogenetic information in Swiss drug labels – a systematic analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…All intervention sessions were conducted between 4 and 6 p.m. for approximately 40 to 50 min. Standard inpatient treatment for all patients consisted of pharmacological treatment according to Swiss national recommendations [ 39 ], individual and group-psychotherapy supported by a number of creative group therapies. However, participants were asked to refrain from any additional vigorous physical activities during the intervention period.…”

Section: Methodsmentioning

confidence: 99%

Aerobic Exercise and Stretching as Add-On to Inpatient Treatment for Depression Have No Differential Effects on Stress-Axis Activity, Serum-BDNF, TNF-Alpha and Objective Sleep Measures

et al. 2021

View full text Add to dashboard Cite

(1) Background: While the antidepressant effects of aerobic exercise (AE) are well documented, fewer studies have examined impact of AE as an add-on treatment. Moreover, various effects on neurobiological variables have been suggested. This study examines effects of AE on Cortisol Awakening Reaction (CAR), serum Brain Derived Neurotrophic Factor (sBDNF), Tumor Necrosis Factor alpha (TNF-alpha) and sleep. (2) Methods: Inpatients with moderate-to-severe depression (N = 43) were randomly assigned to the AE or stretching condition (active control) taking place 3x/week for 6 weeks. CAR, sBDNF and TNF-alpha were assessed at baseline, after 2 weeks and post-intervention. The 17-item Hamilton Depression Rating Scale (HDRS17), subjective sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI) and polysomnography (PSG) were obtained at baseline and post-intervention. (3) Results: Stress axis activity decreased in both groups from baseline to post-intervention. sBDNF showed a significant increase over time, whereas the number of awakenings significantly decreased. No significant time by group interactions were detected for any of the study variables. Correlational analyses showed that higher improvements in maximum oxygen capacity (VO2max) from baseline to post-intervention were associated with reduced scores on the HDRS17, PSQI and REM-latency post-intervention. (4) Conclusions: While some neurobiological variables improved during inpatient treatment (CAR, sBDNF), no evidence was found for differential effects between AE and an active control condition (stretching). However, patients in which cardiorespiratory fitness increased showed higher improvements in depression severity and depression-related sleep-parameters.

show abstract

“…All intervention sessions took place in the late afternoon (between 4 and 6 p.m.) for approximately 40 to 50 min. All patients underwent standard inpatient treatment consisting of pharmacological treatment according to Swiss national standards (27) and individual and group psychotherapy supported by an array of creative group therapies. However, participants were asked not to engage in any additional vigorous exercise activities during their stay at the hospital.…”

Section: Methodsmentioning

confidence: 99%

Effects of Aerobic Exercise as Add-On Treatment for Inpatients With Moderate to Severe Depression on Depression Severity, Sleep, Cognition, Psychological Well-Being, and Biomarkers: Study Protocol, Description of Study Population, and Manipulation Check

et al. 2019

View full text Add to dashboard Cite

Background: Aerobic exercise (AE) may be a non-pharmacological strategy to improve depression treatment and lessen the burden of somatic comorbidity of depression. Only few studies have examined the effect of AE as an add-on treatment for moderate to severe depression in an inpatient setting, and most studies have focused on depression severity and cardiovascular parameters. The purpose of the present article is to present the study protocol, to provide information about the assessed study population, and to perform a manipulation check in order to examine whether the intervention program was properly implemented. Methods: We conducted a randomized controlled trial in two centers comparing 6 weeks of AE to a placebo control intervention (stretching) as an add-on to standardized inpatient treatment of moderate to severe depression. Besides depression severity, several other psychological and biological variables were measured such as salivary cortisol, brain-derived neurotropic factor, cognitive tests, and polysomnography. To evaluate long-term effects of the intervention, we also scheduled a follow-up 6 months after completion of the study intervention. Results: Forty-five patients were randomized to either AE ( n = 23) or the placebo intervention ( n = 22); 36 patients completed the 6-week intervention. In the AE group, 65% completed all 18 training sessions. Patients who were less physically active prior to admission were less likely to complete the study. With regard to energy expenditure, mean kcal/kg/week was 16.4 kcal/kg/week (range: 13.8–17.7), coming close to the targeted dose of 17.5 kcal/kg/week. Conclusions: Overall, patients showed good adherence to the intervention protocol despite at least moderate depression severity. However, the dropout rate suggests that depressed inpatients may need special support to adhere to a structured exercise intervention program. This study will add evidence on the effects of AE as an add-on to inpatient treatment of moderate to severe depression. Besides antidepressant effects, potentially beneficial effects of AE on a broad array of further variables associated with depression will be evaluated. Clinical Trial Registration: , identifier NCT02679053.

show abstract

Die somatische Behandlung der unipolaren depressiven Störungen. Teil 1

Cited by 6 publications

References 6 publications

Pharmacogenetic information in Swiss drug labels – a systematic analysis

Pharmacogenetic information in Swiss drug labels – a systematic analysis

Aerobic Exercise and Stretching as Add-On to Inpatient Treatment for Depression Have No Differential Effects on Stress-Axis Activity, Serum-BDNF, TNF-Alpha and Objective Sleep Measures

Effects of Aerobic Exercise as Add-On Treatment for Inpatients With Moderate to Severe Depression on Depression Severity, Sleep, Cognition, Psychological Well-Being, and Biomarkers: Study Protocol, Description of Study Population, and Manipulation Check

Contact Info

Product

Resources

About